Nature Communications has accepted and published research by Prescient’s Amol Padgaonkar:
“Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease”
Resistance to chemotherapy remains a critical problem for patients diagnosed with triple negative breast cancer (TNBC). This publication identifies a potent multi-kinase inhibitor of cancer stem cells (CSC) that suppresses TNBC growth and overcomes resistance to chemotherapy. Effective inhibition of chemotherapy-resistant TNBC, particularly in the CSC subpopulation, using targeted oncogenic kinase inhibition could lead to dramatic improvements in morbidity and mortality associated with TNBC.